CJC-1295 No DAC/Ipamorelin Blend Dosage, Reconstitution & Mixing Trends

Explore cjc-1295 no dac/ipamorelin blend calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized cjc-1295 no dac/ipamorelin blend calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What CJC-1295 No DAC/Ipamorelin Blend Is

This blend pairs CJC-1295 without DAC (Mod GRF 1-29) with ipamorelin, and is one of the most-sourced growth-hormone-axis research combinations. It ships as a co-lyophilized powder reconstituted with bacteriostatic water before use.[1]

CJC-1295 no-DAC stimulates the pituitary somatotrophs through the GHRH receptor while ipamorelin acts on the parallel ghrelin/GHS-R1a pathway. Used together the two peptides produce a synergistic, pulsatile GH release that preserves the body's natural circadian GH rhythm, in contrast to recombinant hGH which abolishes endogenous pulsatility.[2]

Published research is limited to the parent peptides individually — a Phase 1 study of CJC-1295 no-DAC in healthy adults (Teichman et al., JCEM 2006) documented dose-dependent IGF-1 elevation,[2] and ipamorelin was characterized for GH selectivity by Raun et al. (Eur J Endocrinol 1998).[3] No published trials evaluate the combination as a fixed-ratio research blend.

Neither component is FDA-approved. CJC-1295 and ipamorelin both appear on the FDA 503A "do not compound" interest list (2023). Research-only material.

CJC-1295 No DAC/Ipamorelin Blend Research Sources

CJC-1295 No DAC/Ipamorelin Blend Dosing Context

CJC-1295 No DAC/Ipamorelin Blend has a reported half-life of ~30 min (CJC) and ~2 hr (Ipamorelin). The pharmacokinetic reference models an interval of once daily (before bed); this is not a measured community cadence or a dosing recommendation. Both components are short-acting — they work as a pulse rather than a steady-state level. The CJC-1295 (no DAC) component clears within an hour; Ipamorelin within a few hours. Pharmacokinetic source: Walker 1991 and Raun 1998 component data. CJC-1295 No DAC/Ipamorelin Blend is a blend of CJC-1295 (no DAC) and Ipamorelin, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Muscle Peptides on WPA.

CJC-1295 No DAC/Ipamorelin Blend Community Calculator Data

11,214 CJC-1295 No DAC/Ipamorelin Blend reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

CJC-1295 No DAC/Ipamorelin Blend Research Background and Calculator Data

CJC-1295 No DAC + Ipamorelin is a deliberate two-peptide pairing that combines a short-acting GHRH analog with a selective GHRP, and the rationale traces to two separate strands of growth-hormone-axis research. The DAC — Drug Affinity Complex — is a chemical linker built into the original CJC-1295 molecule that binds to albumin (the most abundant protein circulating in the blood) immediately after injection, stretching the peptide's active life from about 30 minutes to roughly 7 to 8 days. That long residence creates a slow, continuous GH stimulus instead of the sharp natural pulses the pituitary normally produces — which is why protocols focused on pulsatile release deliberately use the No DAC form. CJC-1295 without the linker is functionally identical to Modified GRF 1-29 — a 30-amino-acid GHRH analog with a half-life of roughly 30 minutes, designed to fire a clean, pulse-shaped GHRH signal at the pituitary somatotrophs. Ipamorelin sits on the other side of the receptor pair: it is a selective GHRP first described in Raun et al. 1998 (European Journal of Endocrinology) and characterized as the first GHRP that releases growth hormone with essentially no cortisol, prolactin, or aldosterone elevation — a profile distinctly cleaner than GHRP-2 or GHRP-6, which had been the GHRP standards through the 1990s. Stacking the two is grounded in the synergy described across the GHRH/GHRP literature and synthesized in the Sigalos & Pastuszak 2018 review (Sexual Medicine Reviews): the GHRH side raises pulse amplitude by signalling at pituitary GHRH receptors, the GHRP side both amplifies that amplitude and acts on the ghrelin receptor pathway, and the combined effect is consistently larger than either peptide alone — published GHRH/GHRP crossover studies report combined GH pulses running 2 to 4 times larger than either compound given in isolation. For a deeper look at how this stack fits a full GH-axis protocol, see the WPA HGH Peptide Stack Guide.

What the published record does not contain is a labeled human therapeutic indication for either compound in this combination — neither modified GRF 1-29 nor ipamorelin holds an FDA approval, and the combination has never been formally trialed at the large Phase 3 scale the FDA requires for drug approval.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.